Thromboprophylaxis following Caesarean Section

Summary

Pharmacological thromboprophylaxis is increasingly being used after caesarean section to prevent venous thromboembolism. Although a variety of low molecular weight heparins (LMWH) have been used no comparative study exists on their effects on the haemostatic system in this situation. Furthermore, their antithrombotic effect may be mediated through effects other than their inhibitory effect on activated factor X. We compared the plasma anti-factor Xa activity, plasma concentration of tissue factor pathway inhibitor (TFPI) and the reduction in plasma thrombin-antithrombin (TAT) complex concentration in 30 women randomised to receive either dalteparin 5,000 IU anti-Xa once daily (n = 10), enoxaparin 4,000 IU anti-Xa once daily (n = 10) or tinzaparin 50 IU/kg anti-Xa (average dose 3,650 anti-Xa units) once daily (n = 10) following caesarean section. Sampling occurred at 0, 1, 3, 6, 12 and 24 h relative to time of dosing. All preparations produced an increase in mean anti-Xa assay (p <0.0001), a reduction in mean TAT (p <0.05) and an increase in mean TFPI concentration (p <0.05). Analysis of variance (ANOVA) revealed a significant difference between the LMWHs in terms of mean anti-factor Xa activity (p <0.005) and reduction in plasma TAT concentration (p <0.005). Post hoc analysis indicated that the anti-Xa values of the groups receiving enoxaparin and dalteparin were significantly higher than those of the group receiving tinzaparin (p <0.05), but not significantly different from each other. Post hoc analysis of the reduction in plasma TAT concentration showed the reduction to be significantly less in the group receiving enoxaparin compared to the dalteparin and tinzaparin groups (p <0.05), which did not differ significantly from each other. There was no significant difference between treatment groups with regard to plasma concentration of TFPI. These findings demonstrate that LMWHs differ in their effects on haemostatic parameters including thrombin generation as assessed by TAT. The increase in TFPI may be an additional mediator of LMWH’s antithrombotic effects. Although these findings demonstrate that LMWHs differ in their haemostatic effects, this does not necessarily infer a clinical difference between these agents.

Keywords

Low molecular weight heparin (LMWH) - pregnancy - anti-factor Xa - tissue factor pathway inhibitor - thrombin-antithrombin (TAT) complex

• References

• 1 Department of Health, Welsh Office, Scottish Home and Health Department and Department of Health and Social Services Northern Ireland.. Confidential Enquiries into Maternal Deaths in the United Kingdom 1994-1996. London: HMSO; 1998
• 2 Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353 9160 1258-65.
• 3 Report of the Royal College of Obstetricians and Gynaecologists working party on Prophylaxis Against Thromboembolism in Gynaecology and Obstetrics (1995). London: RCOG.;
• 4 Thromboembolic Risk Factors (THRIFT) Consensus Group.. Risk and Prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567-74.
• 5 Gibson JL, Ekevall K, Walker I, Greer IA. Puerperal thromboprophylaxis: comparison of the anti-Xa activity of enoxaparin and unfractionated heparin. Br J Obstet Gynaecol 1998; 105: 795-7.
• 6 Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. In: Balliere’s Clinical Obstetrics and Gynaecology, Thromboembolic Disease in Obstetrics and Gynaecology. Greer IA. ed. Cambridge: Balliere Tindall; 1997: 489-509.
• 7 ten Cate H, Lamping RJ, Henny CP, Prins A, and ten Cate JW. Automated amidolytic method for determining heparin, a heparinoid and a low-MW heparin fragment, based on their anti-Xa activity. Clinical Chemistry 1984; 30: 860-4.
• 8 Pelzer H, Schwartz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1998; 59: 101-6.
• 9 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
• 10 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low molecular weight heparins: Pharmacologic profile and product differentiation. Am J Cardiol 1998; 82: 3L-10L.
• 11 Eriksson BI, Soderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low molecular weight heparins (LMWH) and unfractionated heparin (UFH) in healthy volunteers. Thromb Haemost 1993; 69: 656 (Abstr 410).
• 12 Brennand JE, Walker ID, Greer IA. Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol 1999; 101: 53-5.
• 13 Planes A, Samama MM, Lensing AW, Buller HR, Barre J, Vochelle N, Beau B. Prevention of deep vein thrombosis after hip replacement – comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81 (Suppl. 01) 22-5.
• 14 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of the extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1998; 50: 803-13.
• 15 Novotny WF, Palmier M, Wun TC, Broze Jr GJ, Miletich JP. Pureficiations and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991; 78: 394-400.
• 16 Harenberg J, Siegele M, Dempfle CE, Stehle G, Heene DL. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost 1993; 70: 942-5.
• 17 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same?. Semin Thrombos Haemostas 1996; 22: 77-91.
• 18 Siragusa S, Cosmi B, Barone M, Beltrametti C, Serafini S, Piovella F. Low molecular weight heparins: are different preparations comparable in the treatment of venous thromboembolism. Blood 1997; 90 (Suppl. 01) 3264.
• 19 Simmoneau G, Sors H, Charbonnier B. et al. A comparison of low molecular weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-9.